Lawrence A. Leiter


Associate Scientist, Li Ka Shing Knowledge Institute


Please note: Dr. Leiter is not taking any summer students in 2019.

Dr. Lawrence A. Leiter is Director of the Lipid Clinic, Associate Director of the Clinical Nutrition and Risk Factor Modification Centre and an Associate Scientist in the Li Ka Shing Knowledge Institute of St. Michael’s Hospital in Toronto.  From 2000-2010, he was Head of the Division of Endocrinology and Metabolism. He is a Professor in the Departments of Medicine and Nutritional Sciences at the University of Toronto.

Dr. Leiter has several research interests including clinical trials on the prevention of atherosclerosis, especially in diabetes, and the dietary and pharmacologic treatment of diabetes mellitus, hyperlipidemia, hypertension, and obesity. He has over 500 publications in peer-reviewed journals. He was an investigator in many of the landmark diabetes trials including the Diabetes Control and Complications Trial (DCCT), Action to Control Cardiovascular Risk in Diabetes (ACCORD), and Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) and is on the Steering Committees of many ongoing outcome trials in both the diabetes and lipid areas.

Dr. Leiter is the past President of the Canadian Society of Endocrinology & Metabolism (CSEM) and is a past Chair of the Clinical and Scientific Section of the Canadian Diabetes Association (CDA). He has been involved in many national and international committees and consensus conferences including those of the International Diabetes Federation, CDA, Canadian Hypertension Education Program (CHEP), Canadian Cardiovascular Society (Dyslipidemia), and Obesity Canada.

For his work, he has received a number of awards including the CDA Frederick G. Banting Award and the American Diabetes Association Charles H Best Award (awarded to DCCT investigators), both for Distinguished Service. He also received the 2005 CSEM Educator of the Year Award, and the 2006 CDA Gerald S. Wong Award in recognition of significant contributions to the diabetes community. In 2016, Dr. Leiter received the Canadian Diabetes Association Long Term Achievement Award for Research and the Canadian Society of Endocrinology’s Robert Volpe Award. He was also the inaugural winner of the St. Michael’s Hospital Complete Physician Award in 2009.


Recent Publications

  1. Davidson, JA, Desouza, C, Fonseca, V, Frias, JP, Van Gaal, L, Giorgino, F et al.. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials. Diabet. Med. 2019; :. doi: 10.1111/dme.14094. PubMed PMID:31365765 .
  2. Ballantyne, CM, Laufs, U, Ray, KK, Leiter, LA, Bays, HE, Goldberg, AC et al.. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2019; :2047487319864671. doi: 10.1177/2047487319864671. PubMed PMID:31357887 .
  3. Verma, S, Leiter, LA, Latter, DA, Bhatt, DL. A LEADER in the management of type 2 diabetes and cardiorenal disease. J. Thorac. Cardiovasc. Surg. 2019; :. doi: 10.1016/j.jtcvs.2019.03.134. PubMed PMID:31227180 .
  4. Mosenzon, O, Wiviott, SD, Cahn, A, Rozenberg, A, Yanuv, I, Goodrich, EL et al.. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7 (8):606-617. doi: 10.1016/S2213-8587(19)30180-9. PubMed PMID:31196815 .
  5. Gerstein, HC, Colhoun, HM, Dagenais, GR, Diaz, R, Lakshmanan, M, Pais, P et al.. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394 (10193):121-130. doi: 10.1016/S0140-6736(19)31149-3. PubMed PMID:31189511 .
  6. Gerstein, HC, Colhoun, HM, Dagenais, GR, Diaz, R, Lakshmanan, M, Pais, P et al.. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394 (10193):131-138. doi: 10.1016/S0140-6736(19)31150-X. PubMed PMID:31189509 .
  7. Sabatine, MS, Giugliano, RP, Leiter, LA. Correctly understanding the diabetes data in FOURIER. Diabetes Obes Metab. 2019; :. doi: 10.1111/dom.13812. PubMed PMID:31183961 .
  8. Leiter, LA, Bain, SC, Hramiak, I, Jódar, E, Madsbad, S, Gondolf, T et al.. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18 (1):73. doi: 10.1186/s12933-019-0871-8. PubMed PMID:31167654 PubMed Central PMC6551895.
  9. Ayoub-Charette, S, Liu, Q, Khan, TA, Au-Yeung, F, Blanco Mejia, S, de Souza, RJ et al.. Important food sources of fructose-containing sugars and incident gout: a systematic review and meta-analysis of prospective cohort studies. BMJ Open. 2019;9 (5):e024171. doi: 10.1136/bmjopen-2018-024171. PubMed PMID:31061018 PubMed Central PMC6502023.
  10. Dash, S, Leiter, LA. Residual cardiovascular risk among people with diabetes. Diabetes Obes Metab. 2019;21 Suppl 1 :28-38. doi: 10.1111/dom.13646. PubMed PMID:31002458 .
Search PubMed

Affiliations & Other Activities

  • Director, Lipid Clinic, St. Michael’s Hospital
  • Associate Director, Clinical Nutrition and Risk Factor Modification Centre, St. Michael’s Hospital
  • Professor, Departments of Medicine and Nutritional Sciences, University of Toronto